About: Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
Creator	Chen, Lan Xiao, Xiong Chen, Hui-Min Chen, Xian-Li Feng, Zhi-Peng Fu, Jian-Guo Han, Qiu-Ying Hu, Lan Liu, Li-Long Wang, Jun-Hui Yin, Zhen-Yu Zhang, Su-Zhen Zhang, Xiao-Bin Zhang, Zhen-Yu Zhong, De-Jin She, Dan-Yang Lan, Yu-Pei Yu, Xing-Hua Zhu, Yong-Hong
Source	MedRxiv
abstract	The outbreak of novel coronavirus disease 2019 (COVID-19) has become a pandemic. Drug repurposing may represent a rapid way to fill the urgent need for effective treatment. We evaluated the clinical utility of chloroquine and hydroxychloroquine in treating COVID-19. Forty-eight patients with moderate COVID-19 were randomized to oral treatment with chloroquine (1000 mg QD on Day 1, then 500 mg QD for 9 days; n=18), hydroxychloroquine (200 mg BID for 10 days; n=18), or control treatment (n=12). Adverse events were mild, except for one case of Grade 2 ALT elevation. Adverse events were more commonly observed in the chloroquine group (44.44%) and the hydroxychloroquine group (50.00%) than in the control group (16.67%). The chloroquine group achieved shorter time to clinical recovery (TTCR) than the control group (P=0.019). There was a trend toward reduced TTCR in the hydroxychloroquine group (P=0.049). The time to reach viral RNA negativity was significantly faster in the chloroquine group and the hydroxychloroquine group than in the control group (P=0.006 and P=0.010, respectively). The median numbers of days to reach RNA negativity in the chloroquine, hydroxychloroquine, and control groups was 2.5 (IQR: 2.0-3.8) days, 2.0 (IQR: 2.0-3.5) days, and 7.0 (IQR: 3.0-10.0) days, respectively. The chloroquine and hydroxychloroquine groups also showed trends toward improvement in the duration of hospitalization and findings on lung computerized tomography (CT). This study provides evidence that (hydroxy)chloroquine may be used effectively in treating moderate COVID-19 and supports larger trials.
has issue date	2020-06-22(xsd:dateTime)
bibo:doi	10.1101/2020.06.19.20136093
has license	medrxiv
sha1sum (hex)	23c75bc4b9be3be448cadd80d6a53473295f5679
schema:url	https://doi.org/10.1101/2020.06.19.20136093
resource representing a document's title	Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
resource representing a document's body	covid:23c75bc4b9be3be448cadd80d6a53473295f5679#body_text
is schema:about of	named entity 'coronavirus disease 2019' named entity 'COVID-19' named entity 'pandemic' named entity 'prospective' named entity 'COVID-19' named entity 'chloroquine' named entity 'open-label' named entity 'healthcare professionals' named entity 'quinolones' named entity 'Hydroxychloroquine' named entity 'chloroquine phosphate' named entity 'treatment groups' named entity 'cough' named entity 'symptomatic treatment' named entity 'control arm' named entity 'chloroquine' named entity 'Kaplan-Meier' named entity 'rheumatoid arthritis' named entity 'chloroquine' named entity 'Wuhan' named entity 'peer review' named entity 'CT scan' named entity 'chloroquine' named entity 'antiviral activity' named entity 'Il-8' named entity 'chloroquine' named entity 'COVID-19' named entity 'medRxiv' named entity 'crisis intervention' named entity 'COVID' named entity 'loading dose' named entity 'hydroxychloroquine' named entity 'IL-1' named entity 'chloroquine' named entity 'SARS-CoV-2' named entity 'chloroquine' named entity 'peer review' named entity 'preprint' named entity 'preprint' named entity 'hydroxychloroquine' named entity 'significant difference' named entity 'interquartile range' named entity 'hydroxychloroquine' named entity 'medRxiv' named entity 'chest CT scan' named entity 'chloroquine' named entity 'placebo-controlled' named entity 'IL-10' named entity 'hydroxychloroquine' named entity 'cytokine storms' named entity 'complete blood count' named entity 'hydroxychloroquine' named entity 'chloroquine' named entity 'Zika' named entity 'COVID-19' named entity 'cardiac enzyme' named entity 'peer review' named entity 'COVID-19' named entity 'antibody' named entity 'peer review' named entity 'point estimation' named entity 'asymptomatic' named entity 'hydroxychloroquine' named entity 'IgG/IgM' named entity 'chloroquine' named entity 'plasma' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software